viewAnteris Technologies Ltd

Admedus progressing to animal trials of its unique heart valve device

The 3D valve recently passed a critical viability test, successfully completing more than 200 million simulated cycles.

a human body
Admedus’ development portfolio continues to gain momentum

Admedus Ltd (ASX:AHZ) is entering the next stage in the development of its Transcatheter Aortic Valve Replacement (TAVR) project by signing an agreement to commence animal trials in a leading European laboratory.

Beginning in July, the experimental study will use sheep to examine the safety and feasibility of Admedus’ unique 3D single-piece moulded valve.

After an initial trial period of about three months, the study will extend to larger animals (calves) for testing the valves in a TAVR setting.

The experiments are expected to be completed by early 2019.

READ: Admedus signs deal to market its heart tissue products in Spain and Portugal

The TAVR device offers benefits to patients and physicians through novel engineering and leveraging the unique capabilities of the company’s clinically-superior ADAPT® tissue.

Admedus chief executive officer Wayne Paterson said: “Admedus’ development portfolio continues to gain momentum as we push into new product areas and expand on the application of our clinically-superior ADAPT® technology.

“Our unique ability to create shaped collagen tissue (3D) has opened the door to unprecedented levels of opportunity as we investigate potential new products and applications.

“The 3D valve recently passed a critical viability test, successfully completing more than 200 million simulated cycles which has allowed us to progress to animal trials.”

READ: Admedus secures $6 million to expand medical technologies strategy

The company recently raised about $6 million from institutional and sophisticated investors in a placement at 30 cents per share.

Funds raised will enable the company to expand and progress its strategic projects, including the acceleration of its 3D product portfolio from development to commercialisation.

Admedus is aiming to enter the global TAVR market, currently worth an estimated US$3 billion and projected to reach US$5 billion by 2020.

Quick facts: Anteris Technologies Ltd

Price: 3.94 AUD

Market: ASX
Market Cap: $23.29 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read